Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2015, Article ID 680191, 5 pages
http://dx.doi.org/10.1155/2015/680191
Case Report

Methimazole Associated Neutropenia in a Preterm Neonate Treated for Hyperthyroidism

1St. Christopher’s Hospital for Children, Drexel University College of Medicine, Philadelphia, PA 19134, USA
2Division of Neonatology, Department of Pediatrics, Texas Tech University Health Sciences Center, Odessa, TX 79763, USA

Received 20 November 2014; Revised 13 February 2015; Accepted 13 February 2015

Academic Editor: Suat Simsek

Copyright © 2015 Dimitrios Angelis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. de Groot, M. Abalovich, E. K. Alexander et al., “Management of thyroid dysfunction during pregnancy and postpartum: an endocrine society clinical practice guideline,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 8, pp. 2543–2565, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. McKenzie and M. Zakarija, “Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies,” Thyroid, vol. 2, no. 2, pp. 155–159, 1992. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Rivkees and D. R. Mattison, “Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use,” International Journal of Pediatric Endocrinology, vol. 2009, no. 1, Article ID 132041, 2009. View at Publisher · View at Google Scholar
  4. R. S. Bahn, H. S. Burch, D. S. Cooper et al., “The Role of Propylthiouracil in the Management of Graves’ Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration,” Thyroid, vol. 19, no. 7, pp. 673–674, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Tajiri and S. Noguchi, “Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis,” Thyroid, vol. 14, no. 6, pp. 459–462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. D. S. Cooper, “Antithyroid drugs,” The New England Journal of Medicine, vol. 352, no. 9, pp. 905–917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Akamizu, S. Ozaki, H. Hiratani et al., “Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity,” Clinical and Experimental Immunology, vol. 127, no. 1, pp. 92–98, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Takata, S. Kubota, S. Fukata et al., “Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily,” Thyroid, vol. 19, no. 6, pp. 559–563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. D. S. Cooper, D. Goldminz, A. A. Levin et al., “Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose,” Annals of Internal Medicine, vol. 98, no. 1, pp. 26–29, 1983. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Andersohn, C. Konzen, and E. Garbe, “Systematic review: agranulocytosis induced by nonchemotherapy drugs,” Annals of Internal Medicine, vol. 146, no. 9, pp. 657–665, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Meyer-Gessner, G. Benker, S. Lederbogen, T. Olbricht, and D. Reinwein, “Antithyroid drug—induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature,” Journal of Endocrinological Investigation, vol. 17, no. 1, pp. 29–36, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Yang, J. Zhong, L.-Z. Zhou, T. Hong, X.-H. Xiao, and G.-B. Wen, “Sudden onset agranulocytosis and hepatotoxicity after taking methimazole,” Internal Medicine, vol. 51, no. 16, pp. 2189–2192, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Mutharasan, W. Oatis, H. Kwaan, and M. Molitch, “Delayed anithyroid drug-induced agranulocytosis,” Endocrine Practice, vol. 18, no. 4, pp. e69–e72, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Rivkees, K. Stephenson, and C. Dinauer, “Adverse events associated with methimazole therapy of graves' disease in children,” International Journal of Pediatric Endocrinology, vol. 2010, no. 1, Article ID 176970, 2010. View at Publisher · View at Google Scholar
  15. J. Tajiri, S. Noguchi, S. Okamura et al., “Granulocyte colony-stimulating factor treatment of antithyroid drug- induced granulocytopenia,” Archives of Internal Medicine, vol. 153, no. 4, pp. 509–514, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. L. K. Millar, D. A. Wing, A. S. Leung, P. P. Koonings, M. N. Montoro, and J. H. Mestman, “Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism,” Obstetrics and Gynecology, vol. 84, no. 6, pp. 946–949, 1994. View at Google Scholar · View at Scopus
  17. Z. Nachum, Y. Rakover, E. Weiner, and E. Shalev, “Graves' disease in pregnancy: prospective evaluation of a selective invasive treatment protocol,” The American Journal of Obstetrics and Gynecology, vol. 189, no. 1, pp. 159–165, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Peleg, S. Cada, A. Peleg, and M. Ben-Ami, “The relationship between maternal serum thyroid-stimulating immunoglobulin and fetal and neonatal thyrotoxicosis,” Obstetrics and Gynecology, vol. 99, no. 6, pp. 1040–1043, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Momotani, K. Ito, N. Hamada, Y. Ban, Y. Nishikawa, and T. Mimura, “Maternal hyperthyroidism and congenital malformation in the offspring,” Clinical Endocrinology, vol. 20, no. 6, pp. 695–700, 1984. View at Publisher · View at Google Scholar · View at Scopus
  20. Å. K. Rasmussen, “Cytokine actions on the thyroid gland,” Danish Medical Bulletin, vol. 47, no. 2, pp. 94–114, 2000. View at Google Scholar · View at Scopus
  21. R. Balázs, S. Kovács, W. A. Cocks, A. L. Johnson, and J. T. Eayrs, “Effect of thyroid hormone on the biochemical maturation of rat brain: postnatal cell formation,” Brain Research, vol. 25, no. 3, pp. 555–570, 1971. View at Publisher · View at Google Scholar · View at Scopus
  22. D. R. Hollingsworth and C. C. Mabry, “Congenital graves disease. Four familial cases with long term follow up and perspective,” American Journal of Diseases of Children, vol. 130, no. 2, pp. 148–155, 1976. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Daneman and N. J. Howard, “Neonatal thyrotoxicosis: intellectual impairment and craniosynostosis in later years,” Journal of Pediatrics, vol. 97, no. 2, pp. 257–259, 1980. View at Publisher · View at Google Scholar · View at Scopus
  24. L.-S. Yael, T.-H. Liran, B. Valentina, L.-G. Liat, and P.-H. Orit, “Follow-up of newborns of mothers with Graves' disease,” Thyroid, vol. 24, no. 6, pp. 1032–1039, 2014. View at Publisher · View at Google Scholar
  25. R. Higuchi, T. Kumagai, M. Kobayashi, T. Minami, H. Koyama, and Y. Ishii, “Short-term hyperthyroidism followed by transient pituitary hypothyroidism in a very low birth weight infant born to a mother with uncontrolled Graves' disease,” Pediatrics, vol. 107, no. 4, article E57, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. M. J. E. Kempers, D. A. van Tijn, A. S. P. van Trotsenburg, J. J. M. de Vijlder, B. M. Wiedijk, and T. Vulsma, “Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 12, pp. 5851–5857, 2003. View at Publisher · View at Google Scholar · View at Scopus